176 related articles for article (PubMed ID: 30497918)
1. Clinical experience of chinese herbal medicine ameliorates dermatologic events from epidermal growth factor receptor inhibitors for lung cancer: A case series.
Hung YC; Chin CY; Lee YC; Chen YH; Tsai MY
Explore (NY); 2019; 15(5):363-370. PubMed ID: 30497918
[TBL] [Abstract][Full Text] [Related]
2. Chinese herbal medicine for epidermal growth factor receptor inhibitor-induced skin rash in patients with malignancy: An updated meta-analysis of 23 randomized controlled trials.
Chen ZQ; Li ZY; Yang CZ; Lin RT; Lin LZ; Sun LL
Complement Ther Med; 2019 Dec; 47():102167. PubMed ID: 31780021
[TBL] [Abstract][Full Text] [Related]
3. The Efficacy of Traditional Chinese Herbal Medicine in the Treatment of EGFR Mutated Stage IV Pulmonary Adenocarcinoma Patients Who Received First-Line EGFR-TKI Treatment.
Hung HY; Tseng YH; Liao CM; Chen SY; Wu TP; Lee YC; Chen YM
Integr Cancer Ther; 2017 Mar; 16(1):126-131. PubMed ID: 27151582
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities.
Kim YS; Ji JH; Oh SY; Lee S; Huh SJ; Lee JH; Song KH; Son CH; Roh MS; Lee GW; Lee J; Kim ST; Kim CK; Jang JS; Hwang IG; Ahn HK; Park LC; Oh SY; Kim SG; Lee SC; Lim DH; Lee SI; Kang JH
Oncologist; 2020 Jan; 25(1):e186-e193. PubMed ID: 31492766
[TBL] [Abstract][Full Text] [Related]
5. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ
Trials; 2015 Apr; 16():146. PubMed ID: 25873045
[TBL] [Abstract][Full Text] [Related]
6. Management of Dermatologic Complications of Lung Cancer Therapies.
Pugliese SB; Neal JW; Kwong BY
Curr Treat Options Oncol; 2015 Oct; 16(10):50. PubMed ID: 26338208
[TBL] [Abstract][Full Text] [Related]
7. Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
Shin JU; Park JH; Cho BC; Lee JH
Dermatology; 2012; 225(2):135-40. PubMed ID: 23006507
[TBL] [Abstract][Full Text] [Related]
8. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
Kiyohara Y; Yamazaki N; Kishi A
J Am Acad Dermatol; 2013 Sep; 69(3):463-72. PubMed ID: 23602600
[TBL] [Abstract][Full Text] [Related]
9. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.
Joshi SS; Ortiz S; Witherspoon JN; Rademaker A; West DP; Anderson R; Rosenbaum SE; Lacouture ME
Cancer; 2010 Aug; 116(16):3916-23. PubMed ID: 20564072
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of oral retinoids for treatment of acneiform eruptions induced by epidermal growth factor receptor inhibitors.
Bierbrier R; Lam M; Pehr K
Dermatol Ther; 2022 May; 35(5):e15412. PubMed ID: 35220635
[TBL] [Abstract][Full Text] [Related]
11. Dermatological side effects of targeted antineoplastic therapies: a prospective study.
Agirgol S; Çaytemel C; Pilanci KN
Cutan Ocul Toxicol; 2020 Dec; 39(4):380-384. PubMed ID: 33028137
[TBL] [Abstract][Full Text] [Related]
12. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.
Requena C; Llombart B; Sanmartín O
Cutis; 2012 Aug; 90(2):77-80. PubMed ID: 22988651
[TBL] [Abstract][Full Text] [Related]
13. Topical doxycycline foam 4% for prophylactic management of epidermal growth factor receptor inhibitor skin toxicity: an exploratory phase 2, randomized, double-blind clinical study.
Shacham Shmueli E; Geva R; Yarom N; Hubert A; Keynan R; Kedem TH; Eini M; Tamarkin D; Shirvan M
Support Care Cancer; 2019 Aug; 27(8):3027-3033. PubMed ID: 30607677
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, tolerability and impact on quality of life of clindamycin phosphate and benzoyl peroxide for the treatment of cetuximab-associated acneiform eruption in patients with metastatic colorectal cancer.
Vaccaro M; Guarneri F; Borgia F; Pollicino A; Altavilla G; Cannavò SP
J Dermatolog Treat; 2016; 27(2):148-52. PubMed ID: 26313697
[TBL] [Abstract][Full Text] [Related]
15. EGFR inhibitors: clinical aspects, risk factors and biomarkers for acneiform eruptions and other mucosal and cutaneous adverse effects.
Recuero JK; Fitz JR; Pereira AA; Bonamigo RR
An Bras Dermatol; 2023; 98(4):429-439. PubMed ID: 36990917
[TBL] [Abstract][Full Text] [Related]
16. Prevention and management of acneiform rash associated with EGFR inhibitor therapy: A systematic review and meta-analysis.
Gorji M; Joseph J; Pavlakis N; Smith SD
Asia Pac J Clin Oncol; 2022 Dec; 18(6):526-539. PubMed ID: 35352492
[TBL] [Abstract][Full Text] [Related]
17. Adjunctive Traditional Chinese Medicine Improves Survival in Patients With Advanced Lung Adenocarcinoma Treated With First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs): A Nationwide, Population-Based Cohort Study.
Li CL; Hsia TC; Li CH; Chen KJ; Yang YH; Yang ST
Integr Cancer Ther; 2019; 18():1534735419827079. PubMed ID: 30836771
[TBL] [Abstract][Full Text] [Related]
18. Conventional treatment integrated with Chinese herbal medicine improves the survival rate of patients with advanced non-small cell lung cancer.
Wang CY; Huang HS; Su YC; Tu CY; Hsia TC; Huang ST
Complement Ther Med; 2018 Oct; 40():29-36. PubMed ID: 30219465
[TBL] [Abstract][Full Text] [Related]
19. Spared pre-irradiated area in pustular lesions induced by icotinib showing decreased expressions of CD1a+ langerhans cells and FGFR2.
Zhao Q; Wang YN; Wang B
Jpn J Clin Oncol; 2013 Feb; 43(2):200-4. PubMed ID: 23264674
[TBL] [Abstract][Full Text] [Related]
20. Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment.
Tan AR; Steinberg SM; Parr AL; Nguyen D; Yang SX
Ann Oncol; 2008 Jan; 19(1):185-90. PubMed ID: 17878175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]